相关实验视频
Updated: May 17, 2025

09:05
MicroRNA-based Regulation of Picornavirus Tropism
Published on: February 6, 2017
7.4K
卡里米辛通过降低调节宿主因子TMEM41B对冠状病毒复制表现出广泛的抑制活性
Kun Wang1, Hui-Qiang Wang1, Ge Yang1
1CAMS Key Laboratory of Antiviral Drug Research, Beijing Key Laboratory of Technology and Application for Anti-Infective New Drugs Research and Development, NHC Key Laboratory of Biotechnology of Antibiotics, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, China.
Acta pharmacologica Sinica
|May 15, 2025
概括
卡里米辛通过向宿主蛋白TMEM41B来抑制SARS-CoV-2变异,破坏病毒复制. 这种药物降解了TMEM41B,为抗击冠状病毒提供了新的策略.
科学领域:
- 病毒学 病毒学
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 卡里米辛之前已经证明了泛冠状病毒抑制活性,准进入后复制.
- 该药物干扰病毒蛋白转化和新生病毒RNA合成.
研究的目的:
- 为了研究卡里米辛对新出现的SARS-CoV-2变种的疗效.
- 阐明参与卡里米辛抗病毒作用的特定宿主因素和机制.
主要方法:
- 在Vero E6细胞中对病毒RNA和蛋白质水平的剂量依赖性抑制试验.
- 研究卡里米辛对SARS-CoV-2双膜囊泡 (DMV) 形成的影响.
- 对宿主跨膜蛋白41B (TMEM41B) 在病毒复制和卡里米机制中的作用的分析.
- 生物化学测试以确定卡里米辛与TMEM41B的直接结合及其对TMEM41B无化和降解的影响.
主要成果:
- 卡里米辛剂量依赖于SARS-CoV-2感染细胞中的病毒RNA和蛋白质水平的抑制.
- 卡里米辛破坏了SARS-CoV-2 DMVs的形成,这是一个依赖TMEM41B的过程.
- TMEM41B的过度表达增强了病毒复制,而它的淘汰减少了它,证实了它作为宿主因子的作用.
- 卡里米辛直接与TMEM41B结合,诱导其K48结合的泛化和随后的降解,从而抑制病毒复制.
结论:
- 卡里米辛通过向宿主因子TMEM41B,对抗SARS-CoV-2变种表现出强大的抗病毒活性.
- 药物的机制涉及TMEM41B的降解,破坏病毒复制过程.
- 这些发现加深了对卡里米抗病毒机制的理解,并突出了宿主因素在病毒病原和治疗策略中的重要性.
相关概念视频
Eukaryotic Transcription Inhibitors
9.7K
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
9.7K
Experimental RNAi
6.0K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.0K
MicroRNAs
2.9K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
2.9K
siRNA - Small Interfering RNAs
16.3K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
16.3K
RNA Interference
25.8K
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
25.8K

